Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.40 |
| ▸ | GABRE | P78334 | 1/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.40 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.40 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.40 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28429539 | 1.00 | GABRA1 (0.40) | GABRA1GABRB1GABRA3GABRB2GABRP | |
| SCHEMBL21271480 | 0.83 | TDP1 (0.45) | ALDH1A1RAB9ANPC1SMN1; SMN2GAA | |
| SCHEMBL21271483 | 0.83 | TDP1 (0.45) | ALDH1A1RAB9ANPC1SMN1; SMN2GAA | |
| SCHEMBL20154341 | 0.81 | GABRP (0.44) | GABRA1GABRB1GABRA3GABRB2GABRP | |
| SCHEMBL28423451 | 0.81 | GABRP (0.44) | GABRA1GABRB1GABRA3GABRB2GABRP | |
| SCHEMBL261645 | 0.77 | GABRP (0.47) | GABRA1GABRB1GABRA3GABRB2GABRP | |
| SCHEMBL4117098 | 0.75 | CA1 (0.50) | ALDH1A1KDM4EHPGDRAB9ANPC1 | |
| SCHEMBL4117105 | 0.75 | CA1 (0.50) | ALDH1A1KDM4EHPGDRAB9ANPC1 | |
| SCHEMBL14828663 | 0.73 | GABRP (0.46) | GABRA1GABRB1GABRA3GABRB2GABRP | |
| SCHEMBL2518047 | 0.72 | BAZ2B (0.56) | GABRA1GABRB1GABRA3GABRB2GABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111433207-B | As alpha V Pyrrolopyrazine derivatives of integrin inhibitors | 百时美施贵宝公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-110139864-B | Pyrrole amides as alpha V integrin inhibitors | 百时美施贵宝公司 | 2022-08-23 | — | — | CN | disclosed |
| US-11292802-B2 | Substituted tetrahydropyrrolo[1,2-a]pyrazines as alpha v integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-04-05 | — | — | US | disclosed |
| US-11292802-B2 | Substituted tetrahydropyrrolo[1,2-a]pyrazines as alpha v integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-04-05 | — | — | US | disclosed |
| EP-3707142-B1 | PYRROLOPYRAZINE DERIVATIVES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-12-08 | — | — | EP | disclosed |
| US-20210163501-A1 | PYRROLOPYRAZINE DERIVATIVES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MAYERS SQUIBB COMPANY (US) | 2021-06-03 | — | — | US | disclosed |
| EP-3538528-B1 | PYRROLE AMIDES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10717736-B2 | Pyrrole amides as alpha V integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-21 | — | — | US | disclosed |
| CN-111433207-A | As αVPyrrolopyrazine derivatives of integrin inhibitors | 百时美施贵宝公司 | 2020-07-17 | — | — | CN | disclosed |
| US-20190256512-A1 | PYRROLE AMIDES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-22 | — | — | US | disclosed |
| WO-2018089360-A1 | PYRROLE AMIDES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256512-A1 | PYRROLE AMIDES AS ALPHA V INTEGRIN INHIBITORS | ITGAV, ITGB1, ITGA1 | GABRA1 1262/4885GABRB1 1342/4885GABRA3 1772/4885 |
| US-20210163501-A1 | PYRROLOPYRAZINE DERIVATIVES AS ALPHA V INTEGRIN INHIBITORS | ITGB1, ITGAV, ITGB5 | GABRA1 1326/4885GABRB1 1225/4885GABRA3 1838/4885 |
| US-11292802-B2 | Substituted tetrahydropyrrolo[1,2-a]pyrazines as alpha v integrin inhibitors | ITGB1, ITGAV, ITGA1 | GABRA1 1454/4885GABRB1 1593/4885GABRA3 2359/4885 |
| US-10717736-B2 | Pyrrole amides as alpha V integrin inhibitors | ITGAV, ITGB1, ITGA1 | GABRA1 1262/4885GABRB1 1342/4885GABRA3 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.